吉林大学学报(医学版) ›› 2013, Vol. 39 ›› Issue (2): 352-356.doi: 10.7694/jldxyxb20130236

• 基础研究 • 上一篇    下一篇

不同剂量顺铂周化疗治疗ⅡB期~ⅣA期宫颈癌的疗效评价

王福香,朴金霞,苏清秀,张 矛   

  1. 吉林省肿瘤医院放疗三科,吉林  长春 130012
  • 收稿日期:2012-11-26 出版日期:2013-03-28 发布日期:2013-03-26
  • 通讯作者: 张 矛(Tel:0431-85877258,E-mail:zm19621127@sina.com) E-mail:zm19621127@sina.com
  • 作者简介:王福香(1968-),女,吉林省长春市人,副主任医师,主要从事肿瘤放射治 疗学的研究。
  • 基金资助:

     中国民政部“十一五”期间部级老年学项目资助课题(200718219)

Evaluation on  efficacy of different doses of  weekly cisplatin chemotherapy  in  treatment 
of stage ⅡB-ⅣA cervical cancer 

WANG Fu-xiang ,PIAO Jin-xia,SU Qing-xiu,ZHANG Mao   

  1. Department of Radiotherapy,Jilin Provinal Tumor Hospital,Changchun 130012,China
  • Received:2012-11-26 Online:2013-03-28 Published:2013-03-26

摘要: 目的:观察放疗联合不同剂量顺铂周疗方案治疗中晚期宫颈癌的治疗效果,探寻宫颈癌最佳的治疗方案。方法:收集2007年1月—2008年6月本院收治的符合入组标准的ⅡB~ⅣA期宫颈癌患者135例,按住院序号随机分为单纯放疗45例(单纯放疗组);同步放化疗90例(同步放化疗组),其中顺铂周疗20 mg?m-2低剂量组45例及40 mg/m-2标准剂量组45例。比较单纯放疗组与同步放化疗组患者的3年生存率及相关毒性反应发生率。同时对同步放化
疗组中的2种不同剂量顺铂周疗方案组患者的3年生存率及相关毒性反应发生率进行比较。结果:全组中位随访时间42(6~51)个月。
单纯放疗组患者与同步放化疗组患者3年生存率分别是68.9%和83.3%,2组比较差异有统计学意义(χ2=3.858,P<0.05)。单纯放疗组Ⅲ-Ⅳ级急性毒性反应发生率低于同步放化疗组(χ2=4.072,P<0.05)。同步放化疗组中,20 mg?m-2低剂量组及40 mg/m-2标准剂量组患者的3年生存率分别
为82.2%和84.4%,2组比较差异无统计学意义(χ2=0.090,P>0.05)。20 mg/m-2低剂量组急性毒性反应发生率明显低于40 mg/m-2标准剂量组患者
(χ2=3.920,P<0.05)。结论:与单纯放疗比较,同步放化疗可明显提高ⅡB期~ⅣA期宫颈癌的疗效。在同步放化疗中,与40 mg/m-2标准剂量顺铂比较,20mg/m-2低剂量顺铂可以在不降低患者疗效的同时,降低患者Ⅲ-Ⅳ级急性毒性反应的发生率。

关键词: 顺铂, 宫颈肿瘤, 单纯放疗, 同步放化疗

Abstract: Objective To observe the curative effect of different doses of radiotherapy combined with cisplatin weekly therapy in the treatment of advanced cervi
cal cancer,and to explore better treatment options. Methods 135 cases of stage  ⅡB-ⅣA cervical cancer patients collected in Jilin Provincal Tumor Hospital
 from January 2007 to June 2008 met   the inclusion criteria were randomly divided into radiotherapy group(n=45,radiotherapy alone) and
concurrent chemoradiotherapy group(n=90),including 20 mg/m-2 low dose group(n=45) and 40 mg/m-2 standard dose group(n=45).
The 3-year survival rates and the incidence of related toxic reactions  in radiotherapy group and concurrent chemoradiotherapy group were compar
ed.At the same time the 3-year survival rates and the incidence of related  toxic reactions in 20  mg/m-2 low dose group and 40  mg/m-2 stand
ard dose group were compared.Results The median follow-up time was 42 (6-51) months.The 3-year survival rates  in  radiotherapy group and
  concurrent chemoradiotherapy  group  were 68.9% and 83.3%,the difference was statistically significant (χ2 = 3.858,P<0.05).The in
cidence of Ⅲ-Ⅳ acute toxic reactions in  radiotherapy  group was lower than that in  concurrent chemoradiotherapy group (χ2 = 4.072,P<0.05).The 3-year survival rates in  20 mg/m-2 low dose group and 40  mg?m-2 standard dose group  were 82.2% and 84.4%,there was no significant difference between  two groups (χ2 =0.090,P>0.05).The incidence of acute toxic reactions  in 20 mg/m-2 low dose group was significantly lower than that in  40 mg?m-2 standard
 dose group(χ2 =3.920,P<0.05).Conclusion Compared with radiotherapy alone,concurrent chemoradiotherapy can  significantly improve the efficacy of  ⅡB-ⅣA cervical carcinoma.In the concurrent chemoradiotherapy,compared with  40 mg?m-2 standard dose cisplatin,20 mg/m-2 low dose cisplatin  doesn’t  reduce the effect of radiotherapy in patients,but  reduce the incidence of Ⅲ-Ⅳ stage acute toxic reactions  in patients.


Key words: cisplatin, cervical neoplasms, simple radiotherapy,  ,  ,  , concurrent chemoradiotherapy

中图分类号: 

  • R737